Skip to main content
Premium Trial:

Request an Annual Quote

Structural Bioinformatics Pens Protein Structure Deal with RW Johnson

NEW YORK, Jan 25 – Structural Bioinformatics said Thursday that it had reached a deal to “elucidate” protein structures for The RW Johnson Pharmaceutical Research Institute, a subsidiary of Johnson & Johnson.

“We are extremely pleased to begin a relationship with The R.W. Johnson
Pharmaceutical Research Institute on target structure elucidation,” Edward Maggio, CEO of SBI, said in a statement.

SBI did not disclose financial details or say what targets SBI would work on. The company could not immediately be reached for comment.

In the statement, SBI said it would provide RW Johnson with access to SBI's x-ray crystallography program for “several” undisclosed targets in its drug discovery efforts. Details about SBI’s x-ray crystallography program could not immediately be ascertained. In the past, the company has tended to downplay the need to use x-ray crystallography, focusing attention on its ability to generate protein structures in silico .

SBI is a privately held company based in San Diego.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.